ClinicalTrials.gg
RecruitingNCT06962839Updated Nov 12, 2026

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

A Phase 2 interventional study of BI 1815368 and Placebo in Macular Edema, sponsored by Boehringer Ingelheim. Recruiting at 98 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 12, 2026Site recruiting status changedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 33 under way, 11 of them phase 3. Macular Edema · United States.

Planned enrollment
44th of 244
300 · median 45
Started
2025
with 7 others
Phase 2
63 of 276
3 open now
Primary completion
2028-03
later than 27 of 32 live
Registered
262nd of 276
by date

Among the 276 studies in Macular Edema with a site in United States, this one is the 44th largest by planned enrollment of the 244 interventional ones that give a count, is one of 8 that started in 2025, is one of 63 in phase 2, reaches primary completion later than 27 of the 32 other live ones, and was the 262nd registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Macular Edema with a site in United States, or all of them as a file.
02

Study summary

This study is open to adults 18 and older with an eye condition called diabetic macular edema. People are required to have a specific type of diabetic macular edema called centre-involved diabetic macular edema (CI-DME) to take part. The purpose of this study is to find out whether a medicine called BI 1815368 improves sight in people with CI-DME and to find the most suitable dose.

This study has 2 parts. In the first part, participants are put into 2 groups of equal size randomly, which means by chance. One group takes BI 1815368 tablets and the other group takes placebo tablets. Placebo tablets look like BI 1815368 tablets but do not contain any medicine. In the second part, participants are put into 4 groups of equal size randomly. 3 groups take different daily doses of the study medicine, BI 1815368, while 1 group takes placebo. All participants take tablets twice a day for about 11 months.

Participants are in the study for about 1 year. During this time, they visit the study site at least 16 times. Participants taking metformin have 3 additional study visits. At visits, doctors check the participant's vision and collect information on any health problems. They take detailed pictures of the eye. The changes over time are compared between the groups to see if the treatment works.

03

Conditions studied

  • Macular Edema

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age
  • Diagnosis of diabetes mellitus (DM) (type 1 or type 2), (HbA1c) \<12% treated with stable medication for at least 30 days prior to Day 1; no already-set plans for major changes in DM medication (e.g. start of new medication) at the time of screening and baseline
  • Centre-involved diabetic macular edema (CI-DME) confirmed on spectral domain optical coherence tomography (SD-OCT) with central subfield foveal thickness (CST) ≥320 µm in the study eye at screening
  • Best corrected visual acuity (BCVA) visual acuity Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in the study eye between 24 and 78 (Snellen equivalent range 20/320 to 20/32) at screening Further inclusion criteria apply.

Exclusion criteria

Exclusion criteria:

  • Macular edema considered to be due to other causes than CI-DME in the study eye
  • Proliferative diabetic retinopathy or iris neovascularisation (including the anterior chamber angle) in the study eye
  • Intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) treatment in the study eye is not allowed within 8 weeks prior to Day 1, except for faricimab or aflibercept 8 mg, for which a 16-week prior to Day 1 is required. There is no limit on the total number of prior IVT antiVEGF injections, provided that the subject has demonstrated a response to prior antiVEGF treatment (at the investigator's discretion) and the anatomical integrity is confirmed by the central reading centre (CRC) at screening based on spectral domain optical coherence tomography (SD-OCT).
  • Any history of panretinal photocoagulation, vitreoretinal surgery, IVT or periocular treatment (within 12 months before Day 1), history of fluocinolone ophthalmic implant or dexamethasone IVT implant before Day 1, or topical steroid or nonsteroidal anti-inflammatory drug (NSAID) treatment (within 30 days before Day 1)
  • Prior macular laser photocoagulation performed more than 3 months prior to Day 1 is permitted if absence of scar-like changes within the 1-mm diameter region centred on the fovea is confirmed by the CRC at screening based on SD-OCT
  • Active ocular inflammation or any history of intraocular inflammation within 1 year
  • Aphakia or total absence of the posterior capsule; Yttrium aluminium garnet (YAG) laser capsulotomy in the study eye is permitted if more than 2 months prior to Day 1 Further exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Treatment arm

    Drug: BI 1815368

  • Placebo comparator
    Cohort 1: Placebo arm

    Drug: Placebo

  • Placebo comparator
    Cohort 2: Placebo arm

    Drug: Placebo

  • Experimental
    Cohort 2: Treatment arm, low dose

    Drug: BI 1815368

  • Experimental
    Cohort 2: Treatment arm, medium dose

    Drug: BI 1815368

  • Experimental
    Cohort 2: Treatment arm, high dose

    Drug: BI 1815368

Interventions

  • BI 1815368

  • DrugPlacebo

    Placebo matching BI 1815368

06

What researchers measure

Primary outcomes

  1. Occurrence (yes/no) of a gain of ≥10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters compared with baseline in the study eye at Week 48

    With ETDRS letters, the number of letters a patient can correctly read on an ETDRS chart from a distance of 4 meters is measured.

    Time frame: at baseline, at week 48

Secondary outcomes

  1. Occurrence (yes/no) of gain of ≥15 ETDRS letters compared with baseline in the study eye at Week 48

    With ETDRS letters, the number of letters a patient can correctly read on an ETDRS chart from a distance of 4 meters is measured.

    Time frame: at baseline, at week 48

  2. Occurrence (yes/no) of adverse events (AEs) between the first investigational medicinal product (IMP) dose and end of study (EoS)

    Time frame: up to 52 weeks

  3. Absolute change from baseline in central subfield foveal thickness (CST) as measured by spectral domain optical coherence tomography (SD-OCT) in the study eye at Week 48

    Time frame: at baseline, at week 48

07

Study locations

84 of 98 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a "Document Sharing Agreement". For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Mar 2028, 32 months after the start.

Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's planned 32 months is above that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Sep 2027 → Mar 2028 and completion Sep 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
May 8, 2025
StartActual
Jun 5, 2025
Primary completionEst.
Mar 1, 2028was Sep 2027
CompletionEst.
Mar 29, 2028was Sep 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 3 sites removed. 6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • Budapesti Jahn Ferenc Del-pesti Korhaz es Rendelointezet · Budapest, HungaryNot yet recruiting→Recruiting
  • Arizona Retina & Vitreous Research, Central Phoenix · Phoenix, United StatesNot yet recruiting→Recruiting
  • Eye Research Foundation · Newport Beach, United StatesNot yet recruiting→Recruiting
  • Cleveland Clinic · Cleveland, United StatesNot yet recruiting→Recruiting
  • Retina Consultants of Carolina, P.A. · Greenville, United StatesNot yet recruiting→Recruiting
  • Piedmont Eye Center · Lynchburg, United StatesNot yet recruiting→Recruiting
Show 5 added (2 Japan, 2 United States, 1 Czechia)
  • Vseobecna Fakultni Nemocnice V Praze · Prague, Czechia
  • Chofu Eye Clinic · Chofu-shi, Japan
  • Deep Blue Retina Clinical Research PLLC · Southaven, United States
  • Star Retina · Fort Worth, United States
  • Tokiwadai Muranaka Eye Clinic · tabashi City, Japan
Show 3 removed
  • Vseobecna fakultni nemocnice v Praze · Prague, Czechia
  • Austin Retina Associates · Austin, United States
  • Tokiwadai Muranaka Eye Clinic · Itabashi-ku, Japan
across 3 updates, Oct 1, 2026 – Nov 12, 2026
Primary completion
Sep 1, 2027→Mar 1, 2028
Oct 16, 2026
Study completion
Sep 29, 2027→Mar 29, 2028
Oct 16, 2026
Eligibility
3 exclusion criteria edited, 1 added
What changed in the criteria
Exclusion criteria
  • ChangedBefore Any intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) treatment within 4 months before Day 1 (other than faricimab or aflibercept 8mg), and within 6 months before Day 1 for faricimab or aflibercept 8 mg, and/or more than 4 prior IVT injections with anti-VEGF treatment in total in the study eyeNow Intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) treatment in the study eye is not allowed within 8 weeks prior to Day 1, except for faricimab or aflibercept 8 mg, for which a 16-week washout period prior to Day 1 is required. There is no limit on the total number of prior IVT antiVEGF injections, provided that the subject has demonstrated a response to prior antiVEGF treatment (at the investigator's discretion) and the anatomical integrity is confirmed by the central reading centre (CRC) at screening based on spectral domain optical coherence tomography (SD-OCT).
  • EditedAny history of panretinal photocoagulation, macular laser photocoagulation, vitreoretinal surgery, IVT or periocular corticosteroid treatment (within 12 months before Day 1), history of fluocinolone ophthalmic implant or dexamethasone IVT implant before Day 1, or topical steroid or nonsteroidal anti-inflammatory drug (NSAID) treatment (within 30 days before Day 1)
  • AddedPrior macular laser photocoagulation performed more than 3 months prior to Day 1 is permitted if absence of scar-like changes within the 1-mm diameter region centred on the fovea is confirmed by the CRC at screening based on SD-OCT
  • EditedActive ocular inflammation ofor any history of intraocular inflammation within 1 year
Oct 16, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedOccurrence (yes/no) of drug-related adverse events (AEs) overbetween the treatment period throughfirst investigational medicinal product (IMP) dose and end of study (EoS)Time frame: up to 52 weeks
  • EditedAbsolute change from baseline ofin central subfield foveal thickness (CST) as measured by spectral domain optical coherence tomography (SD-OCT) in the study eye at Week 48Time frame: at baseline, at week 48
Oct 16, 2026
Show all 3 updates
  1. Nov 12, 2026
    3 sites added, 2 sites removed. 5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • Arizona Retina & Vitreous Research, Central Phoenix · Phoenix, United StatesNot yet recruiting→Recruiting
    • Eye Research Foundation · Newport Beach, United StatesNot yet recruiting→Recruiting
    • Cleveland Clinic · Cleveland, United StatesNot yet recruiting→Recruiting
    • Retina Consultants of Carolina, P.A. · Greenville, United StatesNot yet recruiting→Recruiting
    • Piedmont Eye Center · Lynchburg, United StatesNot yet recruiting→Recruiting
    Show 3 added (2 United States, 1 Japan)
    • Deep Blue Retina Clinical Research PLLC · Southaven, United States
    • Star Retina · Fort Worth, United States
    • Tokiwadai Muranaka Eye Clinic · tabashi City, Japan
    Show 2 removed
    • Austin Retina Associates · Austin, United States
    • Tokiwadai Muranaka Eye Clinic · Itabashi-ku, Japan
    + 1 other change: verification date
  2. Oct 16, 2026
    Budapesti Jahn Ferenc Del-pesti Korhaz es Rendelointezet is now Recruiting
    Primary completion Sep 1, 2027→Mar 1, 2028
    Study completion Sep 29, 2027→Mar 29, 2028
    Eligibility 3 exclusion criteria edited, 1 added
    What changed in the criteria
    Exclusion criteria
    • ChangedBefore Any intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) treatment within 4 months before Day 1 (other than faricimab or aflibercept 8mg), and within 6 months before Day 1 for faricimab or aflibercept 8 mg, and/or more than 4 prior IVT injections with anti-VEGF treatment in total in the study eyeNow Intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) treatment in the study eye is not allowed within 8 weeks prior to Day 1, except for faricimab or aflibercept 8 mg, for which a 16-week washout period prior to Day 1 is required. There is no limit on the total number of prior IVT antiVEGF injections, provided that the subject has demonstrated a response to prior antiVEGF treatment (at the investigator's discretion) and the anatomical integrity is confirmed by the central reading centre (CRC) at screening based on spectral domain optical coherence tomography (SD-OCT).
    • EditedAny history of panretinal photocoagulation, macular laser photocoagulation, vitreoretinal surgery, IVT or periocular corticosteroid treatment (within 12 months before Day 1), history of fluocinolone ophthalmic implant or dexamethasone IVT implant before Day 1, or topical steroid or nonsteroidal anti-inflammatory drug (NSAID) treatment (within 30 days before Day 1)
    • AddedPrior macular laser photocoagulation performed more than 3 months prior to Day 1 is permitted if absence of scar-like changes within the 1-mm diameter region centred on the fovea is confirmed by the CRC at screening based on SD-OCT
    • EditedActive ocular inflammation ofor any history of intraocular inflammation within 1 year
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedOccurrence (yes/no) of drug-related adverse events (AEs) overbetween the treatment period throughfirst investigational medicinal product (IMP) dose and end of study (EoS)Time frame: up to 52 weeks
    • EditedAbsolute change from baseline ofin central subfield foveal thickness (CST) as measured by spectral domain optical coherence tomography (SD-OCT) in the study eye at Week 48Time frame: at baseline, at week 48
    + 2 other changes: verification date and description
  3. Oct 1, 2026
    2 sites added, 1 site removed
    Show 2 added (1 Czechia, 1 Japan)
    • Vseobecna Fakultni Nemocnice V Praze · Prague, Czechia
    • Chofu Eye Clinic · Chofu-shi, Japan
    Show 1 removed
    • Vseobecna fakultni nemocnice v Praze · Prague, Czechia

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06962839
Responsible party
Sponsor
First posted
May 8, 2025
Start date
Jun 5, 2025
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 29, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI 1815368

Start the discussion